Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson's Disease

Mission Therapeutics England New York United Kingdom

Builds on preclinical proof-of-concept that MTX325 protects dopamine-producing brain cells by enhancing mitophagy – the process cells use to remove dysfunctional mitochondria  View original content:https://www.prnewswire.co.uk/news-releases/mission-therapeutics-commences-landmark-trial-of-mtx325-a-potential-disease-modifying-treatment-for-parkinsons-disease-302094848.html